{"prompt": "['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 12 of 81', '11.4 Missing data', '70', '11.5 Audit and inspection', '70', '11.6 Archiving', '71', '12. Premature termination of the study', '71', '13. Ethical and legal aspects', '72', '13.1 Investigator(s) and other study personnel', '72', '13.2', 'Funding and financial disclosure', '73', '13.3', 'Ethical and legal conduct of the study', '73', '13.4 Patient information and consent', '74', '13.5 Publication policy and use of data', '75', '13.6 Compensation for health damage of patients / insurance', '75', '13.7 Confidentiality', '75', '14. Reference list', '76', '15. Protocol amendments', '79', '16. Appendices', '79', '16.1 Appendix 1: 6 Minute walk test', '79', '16.2 Appendix 2: Borg CR 10 scale and test instructions', '80', 'Table of tables', 'Table 7-1: Identity of test drug', '29', 'Table 7-2: Identity of matching placebos', '29', 'Table 7-3: Dosing plan', '31', 'Table 7-4: Resumption of study drug intake', '32', 'Table 9-1: Tabular schedule of assessments', '36', 'Table 9-2: KCCQ Domains and Summary Scores', '49', 'Table 9-3: KCCQ - Physical Limitation domain item wording', '50', 'Table of figures', 'Figure 5-1 Study design', '22', 'Figure 10-1 a-allocation for each hypothesis in the ellipse representing the hypothesis', '65']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 13 of 81', 'List of abbreviations', '6MWT', '6 minute walk test', 'ACE', 'angiotensin converting enzyme', 'AE', 'Adverse event', 'AESI', 'Adverse event of special interest', 'AF', 'Atrial fibrillation', 'ALT', 'Alanine aminotransferase', 'ANCOVA', 'Analysis of covariance', 'aPTT', 'Partial Thromboplastin time, activated', 'ARB', 'Angiotensin receptor blocker', 'AST', 'Aspartate aminotransferase', 'AV', 'Atrioventricular', 'BMI', 'Body mass index', 'BNP', 'Brain natriuretic peptide', 'BP', 'Blood pressure', 'bpm', 'Beats per minute', 'BUN', 'Blood urea nitrogen', 'CABG', 'Coronary artery bypass grafting', 'CAD', 'Coronary artery disease', 'CCSA', 'Canadian Cardiovascular Society angina (classification)', 'CEC', 'Central clinical events committee', 'cGMP', 'Cyclic guanosine monophosphate', 'CP', 'Conditional power', 'CR', 'Category Ratio', 'CRO', 'Clinical research organization', 'CSR', 'Clinical study report', 'CSS', 'Clinical Summary Score', 'CV', 'Cardiovascular', 'DBP', 'Diastolic blood pressure', 'dL', 'Deciliter', 'DMC', 'Data monitoring committee', 'e.g.', 'Exempli gratia, for example', 'ECG', 'Electrocardiogram', '(e)CRF', '(Electronic) case report form', 'EDC', 'Electronic data collection', 'EF', 'Ejection fraction', 'eGFR', 'Estimated glomerular filtration rate', 'EoT', 'End of treatment', 'EQ-5D-5L', 'EuroQoL five dimensions five levels questionnaire', 'ESC', 'European Society of Cardiology', 'EU', 'European Union', 'FAS', 'Full analysis set', 'FDA', 'Food and Drug Administration', 'FSH', 'Follicle-stimulating hormone', 'FU', 'Follow up', 'GCL', 'Global clinical lead', 'GCP', 'Good clinical practice', 'GGT', 'Gamma glutamyl transferase', 'GMP', 'Good manufacturing practice', 'Hb', 'Hemoglobin', 'HbAlc', 'Hemoglobin Alc', 'Hct', 'Hematocrit', 'HDL', 'High density lipoprotein', 'HF', 'Heart failure', 'HFpEF', 'Heart failure with preserved ejection fraction']['Clinical Study Protocol', 'No. BAY 1021189 / 19334', '22 FEB 2018', 'Version no. 1.0', 'Page: 14 of 81', 'HFrEF', 'Heart failure with reduced ejection fraction', 'HR', 'Heart rate', 'i.e.', 'Id est, in other words', 'IB', \"Investigator's brochure\", 'International Conference on Harmonization-Good Clinical', 'ICH-GCP', 'Practice', 'IEC', 'Independent ethics committee', 'INR', 'International normalized ratio', 'IR', 'Immediate release', 'IRB', 'Institutional review board', 'IV', 'Intravenous', 'IxRS', 'Interactive voice / web response system', 'K', 'Potassium', 'KCCQ', 'Kansas City Cardiopathy Questionnaire', 'L', 'Liter', 'LA', 'Left atrium, left atrial', 'LAE', 'Left atrial enlargement', 'LAV', 'Left atrial volume', 'lb(s)', 'Pound(s)', 'LDH', 'Lactate dehydrogenase', 'LDL', 'Low density lipoprotein', 'LLOQ', 'lower limit of quantification', 'LS', 'Least squares', 'LSH', 'Life Sciences Data Hub', 'LV', 'Left ventricle, left ventricular', 'LVAI', 'Left volume atrial index', 'LVEF', 'Left ventricular ejection fraction', 'LVH', 'Left ventricular hypertrophy', 'MCH', 'Mean corpuscular hemoglobin', 'MCHC', 'Mean corpuscular hemoglobin concentration', 'MCID', 'Minimal clinically important difference', 'MCV', 'Mean corpuscular volume', 'MD', 'Medical doctor', 'MDRD', 'Modification of Diet in Renal Disease', 'mEq', 'Milliequivalents', 'mg', 'Milligram', 'MDDT', 'Medical Device Development Tool', 'mIU', 'Milli-International Units', 'MID', 'Minimally important difference', 'mL', 'Milliliters', 'min', 'Minute', 'mmHg', 'Millimeters of mercury', 'MMRM', 'Mixed model repeated-measures', 'Na', 'Sodium', 'NA', 'Not applicable', 'NO', 'Nitric oxide', 'NSTEMI', 'Non ST-elevation myocardial infarction', 'NTG', 'Nitroglycerin', 'NT-proBNP', 'N-terminal pro-brain natriuretic peptide', 'NYHA', 'New York Heart Association', 'o.d.', 'Once daily', 'OSS', 'Overall summary score', 'PCI', 'Percutaneous coronary intervention', 'PD', 'Pharmacodynamic(s)', 'PDE5', 'Phosphodiesterase type V', 'pg', 'Picograms', 'PGIC', \"Patient's Global Impression of Change\", 'PGIS', \"Patient's Global Impression of Severity\"]\n\n###\n\n", "completion": "END"}